GRK5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL146226	0.59	4/20
SCHEMBL393772	0.51	4/20
SCHEMBL397851	0.50	4/20
SCHEMBL396165	0.49	4/20
SCHEMBL394470	0.43	4/20
SCHEMBL142711	0.70	3/20
SCHEMBL142827	0.67	3/20
SCHEMBL398242	0.67	3/20
SCHEMBL141073	0.66	3/20
SCHEMBL146065	0.66	3/20
SCHEMBL395020	0.66	3/20
SCHEMBL143621	0.66	3/20
SCHEMBL399057	0.66	3/20
SCHEMBL144942	0.65	3/20
SCHEMBL399276	0.65	3/20
SCHEMBL141063	0.64	3/20
SCHEMBL396403	0.62	3/20
SCHEMBL148379	0.62	3/20
SCHEMBL142344	0.61	3/20
SCHEMBL394524	0.61	3/20

Clinical trials — most relevant to GRK5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Tumor Gene Expression in Women With Ovarian Cancer	PHASE4	COMPLETED
Effect of Symbicort ® on GR in Sputum in COPD	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer	PHASE3	COMPLETED
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma	PHASE2	UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Dose Ranging Study of Carbidopa-levodopa	PHASE2	COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants	PHASE1	COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Inhaled Ciclesonide Study in Preterm Infants	PHASE1	RECRUITING
Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour	nan	UNKNOWN
Acamprosate: Genes Associated With Response	nan	COMPLETED
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
Phenotyping Disease Severity in Asthma	nan	UNKNOWN
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis	nan	COMPLETED
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas	nan	UNKNOWN
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRK5 binder may also engage these)

Protein	Name	Similarity
P43249	—	1.000	P43249 →
Q62833	—	1.000	Q62833 →
Q8VEB1	—	0.998	Q8VEB1 →
GRK4	G protein-coupled receptor kinase 4	0.995	landscape →
O70291	—	0.990	O70291 →
P70507	—	0.986	P70507 →
P97711	—	0.979	P97711 →
GRK6	G protein-coupled receptor kinase 6	0.977	landscape →
O70293	—	0.976	O70293 →
PRKD1	Serine/threonine-protein kinase D1	0.969	landscape →
Q5XIS9	—	0.967	Q5XIS9 →
A0A8I5ZNK2	—	0.964	A0A8I5ZNK2 →
Q8K1Y2	—	0.964	Q8K1Y2 →
Q863I2	—	0.963	Q863I2 →
Q6P9R2	—	0.963	Q6P9R2 →
Q9WTQ1	—	0.962	Q9WTQ1 →
Q8BWW9	—	0.962	Q8BWW9 →
Q3UMW7	—	0.961	Q3UMW7 →
Q62101	—	0.961	Q62101 →
Q8BZ03	—	0.961	Q8BZ03 →
PRKD2	Serine/threonine-protein kinase D2	0.961	landscape →
O88506	—	0.960	O88506 →
Q91604	—	0.959	Q91604 →
Q5GIG6	—	0.958	Q5GIG6 →
Q66H84	—	0.958	Q66H84 →
PRKD3	Serine/threonine-protein kinase D3	0.958	landscape →
A7MBL8	—	0.957	A7MBL8 →
Q5R495	—	0.957	Q5R495 →
Q98TY9	—	0.957	Q98TY9 →
Q9Z1W9	—	0.957	Q9Z1W9 →